| Routes Of Administration: | Inhalation, intravenous |
| Class: | Serotonergic psychedelic |
| Synonyms: | CYB-004; Deuterated dimethyltryptamine; Deuterated DMT; dDMT |
CYB004, or CYB-004, also known as deuterated dimethyltryptamine (dDMT), is a serotonergic psychedelic related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder.[1] [2] [3] [4] It is administered by inhalation or intravenous injection.
It is a tryptamine derivative and is a deuterated analogue and form of DMT. The pharmacodynamic profile of CYB004, including its interactions with serotonin receptors and its effects in animals, is similar to that of DMT. As with DMT, CYB004 is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals.[5] However, CYB004, due to its deuteration, is more resistant to metabolism than DMT and shows a longer elimination half-life (by 2.5- to 2.9-fold) and slower clearance (by 38 to 55%) in animals. The brain to plasma ratio of CYB004 was also increased (by 30%) relative to DMT, indicating slightly greater central permeability as well.
As of August 2024, CYB004 is in phase 2 clinical trials for generalized anxiety disorder. It was also under development for the treatment of substance-related disorders and of other psychiatric disorders, but development for these indications was discontinued. The drug is under development by Cybin. The exact chemical structure of CYB004 (i.e., which hydrogen atoms are deuterated) does not yet seem to have been disclosed. However, Cybin patented deuterated tryptamines, including deuterated forms of DMT like DMT-d10, in 2023.[6] Other related drugs include the deuterated tryptamine CYB003 and the deuterated phenethylamines CYB005 and CYB210010.